Abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer: a real-world retrospective study in China
ConclusionAA is effective and tolerated in asymptomatic or slightly symptomatic mCRPC in “real-life” setting. The survival outcomes are influenced by multiple organ metastasis, hypertension, and radiotherapy. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - May 12, 2023 Category: Endocrinology Source Type: research
Instrumental and transcriptome analysis reveals the chemotherapeutic effects of doxorubicin-loaded black phosphate nanosheets on abiraterone-resistant prostate cancer
In this study, we aimed to understand the molecular mechanisms underlying the development of abiraterone resistance in prostate cancer cells and the potential use of black phosphorus nanosheets (BPNS) for treating abiraterone-resistant prostate cancer. We first established abiraterone-resistant prostate cancer PC-3 cells and found that these cells have higher migration ability than normal prostate cancer cells. Using comparative transcriptomic and bioinformatics analyses between abiraterone-sensitive PC-3 and abiraterone-resistant PC-3 cells, we highlighted the differentially expressed genes (DEGs) involved in the biologic...
Source: Bioorganic Chemistry - May 10, 2023 Category: Chemistry Authors: Haoyang Xu Jiaqi Liu Xiangkai Li Jiawei Li Xiao Lin Zhuowei Li Tong Dou Li Gao Rong Li Keng Po Lai Source Type: research
Instrumental and transcriptome analysis reveals the chemotherapeutic effects of doxorubicin-loaded black phosphate nanosheets on abiraterone-resistant prostate cancer
In this study, we aimed to understand the molecular mechanisms underlying the development of abiraterone resistance in prostate cancer cells and the potential use of black phosphorus nanosheets (BPNS) for treating abiraterone-resistant prostate cancer. We first established abiraterone-resistant prostate cancer PC-3 cells and found that these cells have higher migration ability than normal prostate cancer cells. Using comparative transcriptomic and bioinformatics analyses between abiraterone-sensitive PC-3 and abiraterone-resistant PC-3 cells, we highlighted the differentially expressed genes (DEGs) involved in the biologic...
Source: Bioorganic Chemistry - May 10, 2023 Category: Chemistry Authors: Haoyang Xu Jiaqi Liu Xiangkai Li Jiawei Li Xiao Lin Zhuowei Li Tong Dou Li Gao Rong Li Keng Po Lai Source Type: research
Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer
Oncologist. 2023 Apr 21:oyad102. doi: 10.1093/oncolo/oyad102. Online ahead of print.ABSTRACTVisceral metastasis (VM) and a higher number of bone metastasis generally define high volume/risk in patients with metastatic castration-sensitive prostate cancer (mCSPC). Subgroup analysis of pivotal trials did not show a clear benefit of second-generation non-steroidal anti-androgens (NSAAs) in patients with VM. However, subgroup analysis of the trial assessing abiraterone acetate, a CYP 17 inhibitor, plus prednisone (AAP) showed an improved overall survival (OS) in patients with mCSPC with VM. We searched MEDLINE, Web of Science,...
Source: The Oncologist - April 21, 2023 Category: Cancer & Oncology Authors: Emre Yeked üz Rana R McKay Silke Gillessen Toni K Choueiri Y üksel Ürün Source Type: research
Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer
Oncologist. 2023 Apr 21:oyad102. doi: 10.1093/oncolo/oyad102. Online ahead of print.ABSTRACTVisceral metastasis (VM) and a higher number of bone metastasis generally define high volume/risk in patients with metastatic castration-sensitive prostate cancer (mCSPC). Subgroup analysis of pivotal trials did not show a clear benefit of second-generation non-steroidal anti-androgens (NSAAs) in patients with VM. However, subgroup analysis of the trial assessing abiraterone acetate, a CYP 17 inhibitor, plus prednisone (AAP) showed an improved overall survival (OS) in patients with mCSPC with VM. We searched MEDLINE, Web of Science,...
Source: The Oncologist - April 21, 2023 Category: Cancer & Oncology Authors: Emre Yeked üz Rana R McKay Silke Gillessen Toni K Choueiri Y üksel Ürün Source Type: research
Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study
CONCLUSIONS: In real-world patients with mCSPC, significantly more patients achieved PSA90 with apalutamide than with abiraterone acetate, and this response was achieved earlier with apalutamide.PMID:37080833 | DOI:10.1016/j.urolonc.2023.03.013 (Source: Urologic Oncology)
Source: Urologic Oncology - April 20, 2023 Category: Urology & Nephrology Authors: Benjamin Lowentritt Dominic Pilon Dexter Waters Carmine Rossi Erik Muser Siyana Kurteva Aditi Shah Ibrahim Khilfeh Shawn Du Lorie Ellis Patrick Lefebvre Gordon Brown Source Type: research
Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study
CONCLUSIONS: In real-world patients with mCSPC, significantly more patients achieved PSA90 with apalutamide than with abiraterone acetate, and this response was achieved earlier with apalutamide.PMID:37080833 | DOI:10.1016/j.urolonc.2023.03.013 (Source: Urologic Oncology)
Source: Urologic Oncology - April 20, 2023 Category: Urology & Nephrology Authors: Benjamin Lowentritt Dominic Pilon Dexter Waters Carmine Rossi Erik Muser Siyana Kurteva Aditi Shah Ibrahim Khilfeh Shawn Du Lorie Ellis Patrick Lefebvre Gordon Brown Source Type: research
Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study
CONCLUSIONS: In real-world patients with mCSPC, significantly more patients achieved PSA90 with apalutamide than with abiraterone acetate, and this response was achieved earlier with apalutamide.PMID:37080833 | DOI:10.1016/j.urolonc.2023.03.013 (Source: Urologic Oncology)
Source: Urologic Oncology - April 20, 2023 Category: Urology & Nephrology Authors: Benjamin Lowentritt Dominic Pilon Dexter Waters Carmine Rossi Erik Muser Siyana Kurteva Aditi Shah Ibrahim Khilfeh Shawn Du Lorie Ellis Patrick Lefebvre Gordon Brown Source Type: research
Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study
CONCLUSIONS: In real-world patients with mCSPC, significantly more patients achieved PSA90 with apalutamide than with abiraterone acetate, and this response was achieved earlier with apalutamide.PMID:37080833 | DOI:10.1016/j.urolonc.2023.03.013 (Source: Urologic Oncology)
Source: Urologic Oncology - April 20, 2023 Category: Urology & Nephrology Authors: Benjamin Lowentritt Dominic Pilon Dexter Waters Carmine Rossi Erik Muser Siyana Kurteva Aditi Shah Ibrahim Khilfeh Shawn Du Lorie Ellis Patrick Lefebvre Gordon Brown Source Type: research
Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study
CONCLUSIONS: In real-world patients with mCSPC, significantly more patients achieved PSA90 with apalutamide than with abiraterone acetate, and this response was achieved earlier with apalutamide.PMID:37080833 | DOI:10.1016/j.urolonc.2023.03.013 (Source: Urologic Oncology)
Source: Urologic Oncology - April 19, 2023 Category: Urology & Nephrology Authors: Benjamin Lowentritt Dominic Pilon Dexter Waters Carmine Rossi Erik Muser Siyana Kurteva Aditi Shah Ibrahim Khilfeh Shawn Du Lorie Ellis Patrick Lefebvre Gordon Brown Source Type: research
Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study
CONCLUSIONS: In real-world patients with mCSPC, significantly more patients achieved PSA90 with apalutamide than with abiraterone acetate, and this response was achieved earlier with apalutamide.PMID:37080833 | DOI:10.1016/j.urolonc.2023.03.013 (Source: Urologic Oncology)
Source: Urologic Oncology - April 19, 2023 Category: Urology & Nephrology Authors: Benjamin Lowentritt Dominic Pilon Dexter Waters Carmine Rossi Erik Muser Siyana Kurteva Aditi Shah Ibrahim Khilfeh Shawn Du Lorie Ellis Patrick Lefebvre Gordon Brown Source Type: research
Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study
CONCLUSIONS: In real-world patients with mCSPC, significantly more patients achieved PSA90 with apalutamide than with abiraterone acetate, and this response was achieved earlier with apalutamide.PMID:37080833 | DOI:10.1016/j.urolonc.2023.03.013 (Source: Urologic Oncology)
Source: Urologic Oncology - April 19, 2023 Category: Urology & Nephrology Authors: Benjamin Lowentritt Dominic Pilon Dexter Waters Carmine Rossi Erik Muser Siyana Kurteva Aditi Shah Ibrahim Khilfeh Shawn Du Lorie Ellis Patrick Lefebvre Gordon Brown Source Type: research
Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study
CONCLUSIONS: In real-world patients with mCSPC, significantly more patients achieved PSA90 with apalutamide than with abiraterone acetate, and this response was achieved earlier with apalutamide.PMID:37080833 | DOI:10.1016/j.urolonc.2023.03.013 (Source: Urologic Oncology)
Source: Urologic Oncology - April 19, 2023 Category: Urology & Nephrology Authors: Benjamin Lowentritt Dominic Pilon Dexter Waters Carmine Rossi Erik Muser Siyana Kurteva Aditi Shah Ibrahim Khilfeh Shawn Du Lorie Ellis Patrick Lefebvre Gordon Brown Source Type: research
A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer
ConclusionsCombination therapy of relugolix and abiraterone or apalutamide was associated with a favorable safety and tolerability profile consistent with the known profiles of the individual medications. Castration levels of testosterone were maintained after transitioning to relugolix from other ADTs.Clinical Trial RegistrationClinicalTrials.gov identifier: NCT04666129 (Source: Targeted Oncology)
Source: Targeted Oncology - April 15, 2023 Category: Cancer & Oncology Source Type: research
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
CONCLUSIONS: Median OS was consistent regardless of whether the agents were administered sequentially or concurrently, including after NDI update. Results suggest that sipuleucel-T induces an immunologic prime-boost effect after initial sipuleucel-T exposure, even when combined with ARTAs.PMID:37058234 | DOI:10.1158/1078-0432.CCR-22-3832 (Source: Cell Research)
Source: Cell Research - April 14, 2023 Category: Cytology Authors: Emmanuel S Antonarakis Sumit K Subudhi Christopher M Pieczonka Lawrence I Karsh David I Quinn Jason M Hafron Helen M Wilfehrt Matthew Harmon Nadeem A Sheikh Neal D Shore Daniel P Petrylak Source Type: research
